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hematocrit were 3.2 mg/dL and 46% respectively. At 6 h ofvailable online 25 March 2016
he administration of antenatal and postnatal Rh
mmunoglobulin prophylaxis signiﬁcantly prevents Rh D
lloimmunization during pregnancy. A dose of 20 g anti-D
gG protects against 1 mL  of D-positive red blood cells or 2 mL
f whole blood. Rh D-negative women if unsensitized receive
ntenatal anti-D prophylaxis of 300 g at 28 weeks of preg-
ancy and postnatal prophylaxis if the baby is Rh D positive.
nitial trials concluded that postpartum immunoprophylaxis
ecreased the incidence of Rh D immunization from 12–13%
o 1–2% which was further shown to be reduced to 0.1%
hanks to antenatal prophylaxis.1 Rh immunoglobulin (RhIg)
dministration is quite safe during pregnancy although RhIg
an cross the placenta and cause hemolysis of the red cells
f D-positive fetuses. Unfortunately data is sparse on this
erious adverse event. Herein we  present an unusual case
f hemolytic disease of newborn (HDN) with positive Direct
oombs’ Test (DCT) due to antenatal RhIg prophylaxis in an
h-negative mother.
ase  report
 28-year-old primipara with blood group O Rh negative,
elivered a male baby weighing 2.6 kg at 37+2 weeks by emer-
ency cesarean section in view of fetal bradycardia. During
0 weeks of pregnancy, her antibody screen was negative and
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pen  access article under the CC BY-NC-ND license (http://creativecomshe received a prophylactic dose of 300 g Rh immunoglobulin
(RhIg, Rhogam). She had an otherwise uneventful pregnancy.
Since the mother was Rh D negative, a requisition for blood
grouping, Rh typing and DCT of the baby was made. Blood
group of the baby was O Rh D positive (tube technique). DCT
was performed using column agglutination technology (Ortho
clinical diagnostics, USA) and was found to be positive (3+)
for polyspeciﬁc anti-human globulin (IgG+ C3d) having IgG
speciﬁcity. Anti-D antibody was identiﬁed in the baby’s serum
(Resolve Panel A, Ortho Clinical Diagnostics, USA).
Antibodies were eluted from the baby’s red cells using the
acid elution technique (Diacidel, Bio-Rad, Germany). Antibody
screening was negative for the supernatant of the last wash.
The eluate was positive for anti-D. The mother’s blood group
was O Rh D negative while the father’s blood group was O Rh
D positive. Antibody screening and identiﬁcation of mother’s
sample revealed the presence of anti-D. The anti-D titers of the
eluate and the mother’s sample were 1:4 and 1:8 respectively.
The mother was given 300 g RhIg, 6 h postpartum.
The baby’s Activity, Pulse, Grimace, Appearance, Respi-
ration (APGAR) scores were 8 and 9 at 1 min  and 5 min
respectively. At birth, cord total serum bilirubin (TSB) andda Hospital, Malakpet, Hyderabad 500036, India.
life, TSB was 5.3 mg/dL and it was noticed that the baby
had jaundice. Reticulocytes were 6% (normal range 0.5–2%).
glucose-6-phosphate dehydrogenase (G6PD) deﬁciency testing
 e Terapia Celular. Published by Elsevier Editora Ltda. This is an
mons.org/licenses/by-nc-nd/4.0/).
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Post natal course of the baby
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Figure 1 – Postnatal evolution of the baby with an increase
in total serum bilirubin (TSB) and drop in hematocrit values
r
1
2
3
4
5that responded to phototherapy.
was negative. There was no evidence of sepsis. The child
received phototherapy in view of hyperbilirubinemia as per
our institute protocol. The postnatal evolution of the baby is
shown in Figure 1. Antibody screening of the mother after six
months was negative. Baby had no residual sequelae during
subsequent visits.
Discussion
TSB concentrations above 5 mg/dL on day one of life in a term
neonate indicates pathologic jaundice. Hemolytic anemia
should be considered in the setting of ABO/Rh incompati-
bility, jaundice within 24 h, positive DCT, raised reticulocyte
count, raised serum bilirubin, presence of pallor or evidence
of hemolysis in peripheral blood smear. In this case, along
with these features, antibody titers were low and six-months
follow-up analysis showed negative antibody screening in
mother favoring RhIg induced HDN. Such secondary hemol-
ysis is transient. ABO incompatibility was ruled out. Rh
alloimmunization has occurred even in ﬁrst pregnancy lead-
ing to HDN due to early trimester fetomaternal hemorrhage
or failure of RhIg. In such cases, anti-D will be persistent
being detected in early trimester of second pregnancy.2 Rh
Immunoglobulin generally disappears within 6–8 weeks of
administration.
To the best of our knowledge, this rare case is the ﬁrst report
from India. Incidence of positive direct antiglobulin test (DAT)
6 2 0 1 6;3  8(2):161–162
in babies born to Rh negative mothers ranges from 2 to 30%.
When mothers were given two doses of anti D immunoglobu-
lin antenatally, 20% of the Rh D positive babies showed positive
DAT. In another study, two out of 1238 (0.16%) Rh positive
newborns were affected by passive transfer of maternal RhIg.
Cohen et al. in 2014 reported a case of passive transfer of RhIg
inducing HDN.3 Also a high grade DAT is a strong predictor
of phototherapy.4 Maayan-Metzger et al., in their retrospec-
tive analysis, concluded that there was no signiﬁcant risk
of hemolysis due to RhIg among preterm (28–34 weeks) Rh
D positive babies born to Rh negative mothers and further
prospective studies were required to conﬁrm the correlation.5
To conclude, antenatal and postnatal RhIg prophylaxis for
all Rh-negative mothers who are unsensitized is the standard
practice in vogue. Blood grouping and DCT is mandatory for
all newborns of Rh-negative mothers. Although RhIg admin-
istration to Rh D negative mothers is considered safe, positive
DCT in those D positive neonates should be further evaluated
to rule out the possibility of RhIg induced HDN.  Follow-up
of mother and baby will assist in differentiating hemolysis
caused by Rh immunization from that of RhIg prophylaxis.6
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